Can Anything Stop Johnson & Johnson?

Shares of JNJ beat a new all-time high.

Brenton Flynn
Brenton Flynn
Mar 5, 2013 at 6:19PM
Health Care

Shares of Johnson & Johnson (NYSE:JNJ) hit a new all-time high yesterday and have continued upward today, despite some negative news for the company last night. It was denied FDA approval for the acute coronary syndrome indication of its blood thinning drug Xarelto.

In this video, Motley Fool health-care bureau chief Brenton Flynn tells investors why this highlights a very difficult and very expensive trend for Big Pharma, but also points out that a company as large and diversified as Johnson & Johnson can weather the blow much more easily than some of the smaller players.